David Slack

Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ.